1/36
Vocabulary flashcards covering the key diagnostic terms, neurobiological mechanisms, genetic architectures, and pharmacotherapeutic treatments for substance use and eating disorders.
Psychoactive Substance
Any chemical substance that acts upon the central nervous system to alter brain function, resulting in temporary changes in perception, mood, consciousness, and behavior.
Drug Dependence
The habitual consumption of a substance, which may involve physical dependence where the body neuroadapts to the drug, resulting in a distinct withdrawal syndrome upon cessation.
Substance Abuse
The use of any drug, typically self-administered, in ways that deviate from accepted social norms or medical guidelines.
Substance Misuse
The incorrect or improper use of medications that have been prescribed by healthcare professionals.
Addiction
A condition characterized by compulsive and escalating substance use, marked by distressing symptoms and overwhelming cravings during absence, as well as physical and psychological decline.
Substance Intoxication
A temporary condition induced by a substance that disrupts mental faculties such as memory, awareness, mood, judgment, and social or occupational functioning.
Withdrawal Syndrome
A cluster of physical and psychological symptoms (also termed abstinence or discontinuation syndrome) that emerges when an individual abruptly ceases or reduces chronic, heavy substance use.
Drug Tolerance
A state of decreased drug responsiveness after repeated administration, requiring progressively higher doses to achieve the initial pharmacological impact.
Behavioral Tolerance
An individual's acquired ability to perform motor and cognitive tasks successfully despite being under the active influence of a drug.
Cross-Tolerance (Cross-Dependence)
The phenomenon in which exposure to one drug produces tolerance or dependence to another drug that shares similar physiological and mental mechanisms of action (e.g., diazepam and barbiturates).
SUD Heritability
The proportion of total substance use disorder risk attributable to genetics, established by twin and adoption studies to be between 40% and 60%.
Polygenic Architecture
The genetic basis of addiction liability, which is driven by hundreds to thousands of small-effect genomic variants across the genome rather than a single causal gene.
CHRNA5-CHRNA3-CHRNB4 Cluster
A genomic cluster encoding nicotinic acetylcholine receptor subunits linked to nicotine dependence, accounting for a substance heritability of approximately 60%.
ADH1B and ALDH2 Variants
Genomic variants in alcohol-metabolizing enzymes that provide protective metabolic effects against alcohol use disorder by accelerating acetaldehyde accumulation.
Mesolimbic Dopamine Pathway
The primary reward pathway extending from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), which addictive drugs hijack to elevate synaptic dopamine levels up to 10 times higher than natural rewards.
The Three-Stage Addiction Cycle
A recurring neurobiological framework consisting of: 1) Binge/Intoxication (basal ganglia), 2) Withdrawal/Aversive state (extended amygdala), and 3) Preoccupation/Anticipation (prefrontal cortex).

Epigenetic Remodeling
Chemical modifications such as DNA methylation and histone acetylation induced by trauma, chronic stress, or substance use that alter gene transcription without modifying the underlying DNA sequence.
Incentive Salience ("Wanting")
A subconscious, dopamine-driven motivational urge that transforms neutral stimuli into attention-grabbing "motivational magnets" that compel reward-seeking behavior.
Hedonic Impact ("Liking")
The actual subjective feeling of sensory pleasure experienced during reward consumption, mediated by endogenous opioid and endocannabinoid networks rather than dopamine.
Incentive-Sensitization Theory
A theory developed by Kent Berridge and Terry Robinson positing that addiction results from neural sensitization of mesolimbic "wanting" pathways alongside tolerance-driven reductions in hedonic "liking."
Starvation-Induced Sensitization in Anorexia Nervosa
A misdirected survival mechanism where metabolic deprivation elevates dopamine signaling, attaching incentive salience to fasting, calorie deficits, and exercise instead of food cues.

Ventral-to-Dorsal Striatal Shift
The neurocircuitry transition from ventral striatal (NAc) impulsivity driven by positive reinforcement to dorsal striatal compulsivity driven by negative reinforcement and habit.
Tonic Dopamine Neurotransmission
Slow, steady pacemaker firing (1–8Hz) that targets high-affinity dopamine D2 receptors to maintain baseline mood, motivation, and executive flexibility.
Phasic Dopamine Neurotransmission
Rapid, synchronized burst firing (>15–30Hz for <500ms) targeting low-affinity dopamine D1 receptors to signal reward prediction errors and salient stimuli.
Varenicline
A first-line smoking cessation medication that acts as a selective α4β2 nicotinic acetylcholine receptor partial agonist and antagonist, blunting reward and reducing cravings.
Bupropion SR
A first-line smoking cessation medication acting as a dopamine/norepinephrine reuptake inhibitor (NDRI) with weak nAChR antagonism; contraindicated in seizure and eating disorders.
Cytisinicline
A plant-derived alkaloid that functions as a selective partial agonist at α4β2 nicotinic acetylcholine receptors, used as an emerging/regional treatment for smoking cessation.
Naltrexone
A competitive mu-opioid receptor antagonist that blunts alcohol-induced dopamine release and blocks opioid euphoria; contraindicated in acute liver failure or concurrent opioid use.
Acamprosate
A first-line oral medication for alcohol dependence that modulates glutamate (NMDA/mGluR5) and enhances GABA to alleviate protracted withdrawal; eliminated 100% unchanged renally.
Disulfiram
A second-line aversive deterrent for alcohol use that irreversibly inhibits aldehyde dehydrogenase (ALDH), causing toxic acetaldehyde accumulation upon ethanol intake.
Topiramate
An off-label medication that enhances GABAA receptors and inhibits AMPA/kainate receptors, reducing heavy drinking in alcohol use disorder as well as binging in bulimia and BED.
Baclofen
A selective GABAB receptor agonist that suppresses mesolimbic dopamine firing, used off-label to maintain abstinence in patients with advanced alcoholic liver disease or cirrhosis.
Methadone
A long-acting full mu-opioid receptor agonist and weak NMDA antagonist with no respiratory ceiling effect, used as a first-line maintenance treatment for severe opioid use disorder.
Buprenorphine
A high-affinity partial mu-opioid agonist and kappa-opioid antagonist that exhibits a ceiling effect on respiratory depression, requiring mild-to-moderate withdrawal before induction.
Lofexidine
A central α2-adrenergic agonist that blunts locus coeruleus hyperactivity to manage autonomic symptoms during acute opioid withdrawal.
Dual Diagnosis
The clinical condition in which an individual simultaneously meets diagnostic criteria for both a substance use disorder and a co-occurring psychiatric disorder.
Simultaneous Integrated Treatment
The clinical standard for dual diagnosis wherein both substance use and co-occurring psychiatric disorders are managed concurrently by the same multidisciplinary team.